Metachol+: bergamot and artichoke supplement to reduce cholesterol
Official title: Multicenter Randomized Open-label Controlled Clinical Study to Evaluate the Efficacy and Safety of a Nutritional Supplement Based on Bergamot, Artichoke and Other Ingredients After Four Months of Treatment in Reducing Cholesterol Levels in Patients With Moderate or Mild Hypercholesterolemia
Run by Laboratoires Arkopharma · NCT07178769 · Data updated 2026-11-12
This trial tests whether the Metachol+ bergamot-and-artichoke supplement can lower LDL cholesterol in adults with mild-to-moderate high cholesterol.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 207 (estimated) |
| Sponsor | Laboratoires Arkopharma Industry-sponsored |
| Locations | 7 sites (Madrid, Madrid and 6 other locations) |
| Status | Recruiting |
| Started | April 20, 2025 |
| Main results expected | July 30, 2026 |
| Study ends | July 30, 2026 |
| Registry record updated | September 17, 2025 |
| Trial ID | NCT07178769 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with mild-to-moderate cardiovascular risk and LDL cholesterol above 130 mg/dL who can attend visits at Madrid health centers and avoid other lipid-lowering products are the ideal candidates.
✕Probably not a fit
People with severe or decompensated cardiovascular disease, those already taking lipid-lowering medications or supplements, pregnant or breastfeeding individuals, or those allergic to the product ingredients are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with LDL above 130 mg/dL and mild-to-moderate cardiovascular risk are assigned to one of three groups for four months: one capsule nightly, two capsules nightly, or continuing healthy lifestyle habits. The primary outcome is change in LDL cholesterol after four months, with secondary outcomes including full lipid profile, anthropometric measures, vital signs, treatment adherence, safety, and patient satisfaction. Key exclusions include recent use of other lipid-lowering drugs or supplements, decompensated medical conditions, pregnancy or breastfeeding, and allergy to product components. The supplement is supplied by Laboratoires Arkopharma and the trial is run at primary care centers in Madrid.
Why it matters
Potential benefit: If effective, the supplement could provide a non-prescription option to modestly lower LDL cholesterol and improve lipid profiles for some patients.
How similar studies have gone: Some small clinical studies of bergamot-containing supplements have reported modest LDL reductions, but overall evidence is limited and not definitive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who are willing and able to understand and sign the informed consent after the nature of the study has been fully explained to them and they have passed the inclusion/exclusion criteria. 2. Patients aged greater than or equal to 18 years 3. Patients with moderate or mild cardiovascular risk, who have LDL levels greater than 130 mg/dl. Exclusion Criteria: 1. Use of any other drug or food supplement for the treatment of hypercholesterolemia during the 30 days prior to selection. 2. Allergy or hypersensitivity to any of the components of the study treatment. 3. Decompensated cardiovascular disease, decompensated diabetes mellitus, decompensated HTN. 4. Serious medical conditions such as: cancer, serious chronic illness considered incompatible with participation in the study or others that may interfere with the study. 5. HIV-AIDS, Pregnancy or breastfeeding, occlusion of the central retinal artery (of foreseeable vascular origin), history of cardiovascular disease and familial hypercholesterolemia. 6. Liver, kidney or muscle disorders. 7. Psychiatric disorders or inability to sign the consent. 8. Subjects with extreme eating habits and/or with a significant history of anorexia nervosa, bulimia and other eating disorders.
Where it's running
-
Centro de Salud Daroca
Madrid, Madrid, Spain Recruiting -
Centro de Salud Casco Antiguo
Cartagena, Murcia, Spain Recruiting -
Centro de Salud Isaac Peral
Cartagena, Murcia, Spain Recruiting -
Centro de Salud de Mazarrón
Mazarrón, Murcia, Spain Recruiting -
Centro de Salud Goya
Madrid, Madrid, Spain Not yet recruiting -
Centro de Salud Avenida de Aragón
Madrid, Madrid, Spain Not yet recruiting
Show 1 more location
-
Centro de Salud Avenida de Aragón
Madrid, Madrid, Spain Not yet recruiting
Study contacts
- Study coordinator: Lucía San Miguel Amelivia, Pharmacist
- Email: Lucia.SanMiguel@arkopharma.com
- Phone: +34 616960711
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of cancer treatments on metabolism and bone health in early breast cancer survivors
This study is testing how cancer treatments affect metabolism and bone health in post-menopausal women aged 50-70 who have survived early breast cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.